Calif. Stem Cell Agency Aims to Strengthen Ties with Biotech and Pharma Under Updated Strategic Plan | GenomeWeb

By Alex Philippidis

The California Institute for Regenerative Medicine is reviewing a draft update of its strategic plan that calls for it to build relationships with biotechnology and pharmaceutical companies, in hopes of speeding up the development and commercialization of new drugs based on regenerative medicine technologies.

CIRM's draft plan includes among its goals "collaborating with industry," and lays out five strategies designed to fulfill that goal:

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.